Asco 2021 – the exon 20 army lines up behind Rybrevant
A new lung cancer niche is a major focus of Asco, with China's Dizal perhaps boasting the most intriguing dataset.
ERA-EDTA 2021 – Novartis’s iptacopan sets the bar in rare kidney disease
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Asco 2021 – Alkermes’s disappointment hones melanoma niche focus
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
Asco 2021 – Merus’s slight improvement might not win over investors
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.
Asco 2021 justifies Novartis’s radioligand Vision
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
Asco 2021 – Bristol makes more progress in stomach cancer
But the space, a battle between Opdivo and Keytruda, is becoming extremely complex, and Bristol’s win is not unequivocal.
Asco 2021 – financial toxicity in the spotlight
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
Asco 2021 – full Olympia results sweep away Parp doubts
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
